» Articles » PMID: 37358743

Roles of Adenosine Receptor (subtypes A and A) in Cuprizone-Induced Hippocampal Demyelination

Overview
Journal Mol Neurobiol
Date 2023 Jun 26
PMID 37358743
Authors
Affiliations
Soon will be listed here.
Abstract

Hippocampal demyelination in multiple sclerosis (MS) has been linked with cognitive deficits, however, patients could benefit from treatment that induces oligodendroglial cell function and promotes remyelination. We investigated the role of A and A adenosine receptors (AR) in regulating oligodendrocyte precursor cells (OPCs) and myelinating oligodendrocyte (OL) in the demyelinated hippocampus using the cuprizone model of MS. Spatial learning and memory were assessed in wild type C57BL/6 mice (WT) or C57BL/6 mice with global deletion of A (AAR-/-) or A AR (AAR-/-) fed standard or cuprizone diet (CD) for four weeks. Histology, immunofluorescence, Western blot and TUNEL assays were performed to evaluate the extent of demyelination and apoptosis in the hippocampus. Deletion of A and A AR alters spatial learning and memory. In AAR-/- mice, cuprizone feeding led to severe hippocampal demyelination, AAR-/- mice had a significant increase in myelin whereas WT mice had intermediate demyelination. The AAR-/- CD-fed mice displayed significant astrocytosis and decreased expression of NeuN and MBP, whereas these proteins were increased in the AAR-/- CD mice. Furthermore, Olig2 was upregulated in AAR-/- CD-fed mice compared to WT mice fed the standard diet. TUNEL staining of brain sections revealed a fivefold increase in the hippocampus of AAR-/- CD-fed mice. Also, WT mice fed CD showed a significant decrease expression of A AR. A and A AR are involved in OPC/OL functions with opposing roles in myelin regulation in the hippocampus. Thus, the neuropathological findings seen in MS may be connected to the depletion of A AR.

Citing Articles

Astrocyte-derived PTN alleviates deficits in hippocampal neurogenesis and cognition in models of multiple sclerosis.

Song Y, Li H, Li Y, Xu H, Nazir F, Jiang W Stem Cell Reports. 2024; 20(1):102383.

PMID: 39729991 PMC: 11784482. DOI: 10.1016/j.stemcr.2024.11.013.

References
1.
Kerkhofs A, Canas P, Timmerman A, Heistek T, Real J, Xavier C . Adenosine A Receptors Control Glutamatergic Synaptic Plasticity in Fast Spiking Interneurons of the Prefrontal Cortex. Front Pharmacol. 2018; 9:133. PMC: 5869254. DOI: 10.3389/fphar.2018.00133. View

2.
Cunha R . Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal. 2008; 1(2):111-34. PMC: 2096528. DOI: 10.1007/s11302-005-0649-1. View

3.
Linden J, Cekic C . Regulation of lymphocyte function by adenosine. Arterioscler Thromb Vasc Biol. 2012; 32(9):2097-103. PMC: 4476649. DOI: 10.1161/ATVBAHA.111.226837. View

4.
Kashfi S, Ghaedi K, Baharvand H, Nasr-Esfahani M, Javan M . A Adenosine Receptor Activation Modulates Central Nervous System Development and Repair. Mol Neurobiol. 2016; 54(10):8128-8139. DOI: 10.1007/s12035-016-0292-6. View

5.
Jacobson K, Gao Z . Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):247-64. PMC: 3463109. DOI: 10.1038/nrd1983. View